Abstracts tagged "infection and vaccines"

Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 269 • 2017 ACR/ARHP Annual Meeting
Prevalence of Pneumococcal Vaccination in Rheumatologic Patients with Community Acquired Pneumonia. Biobadasar Registry
Gimena Gomez¹, Alejandro Brigante Jr.², Alejandro Benitez³, Osvaldo Cerda⁴, Soledad Retamozo⁵, Ignacio Javier Gandino⁶, Ana Quinteros⁷, Ida Exeni⁴, Belén Barrios⁸, Pablo Astesana⁹, Carolina Sanchez Andia⁴, María Victoria Collado¹⁰, Amelia Granel¹¹, Ana Cappuccio⁴, Rosana Quintana¹², Eduardo Mussano¹³, Andrea Smichowski², Mercedes De La Sota¹⁴, Karin Kirmayr¹⁵, Edson Javier Velozo¹⁶, Maria Silvia Larroude¹⁷, Ana Bertoli¹⁸, Santiago Aguero¹⁹, Cristina Battagliotti²⁰, Sidney Soares de Souza²¹, Emilia Cavillon⁹, Analia Bohr²², Oscar Luis Rillo², Eugenia Bedoya²³, Eduardo Kerzberg²⁴, Boris Kisluk¹², Ingrid Petkovic²⁵, Dora Pereira²⁶, Juan Carlos Barreira², Luis Somma², Ana Carolina Costi²⁷, Belen Virasoro², Fernando Melo²⁸, Sergio Paira²⁹, Luis Roa Perez², Leandro Carlevaris Sr.³⁰, Gustavo Casado⁴ and María Celina de La Vega⁴, ¹on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ²Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ³Sociedad Argentina de Reumatologia, Berazategui, Argentina, ⁴Sociedad Argentina de Reumatologia, CABA, Argentina, ⁵Sociedad Argentina de Reumatologia, Córdoba, Argentina, ⁶Reumatologia, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Sociedad Argentina de Reumatologia, Tucuman, Argentina, ⁸Section of Rheumatology, Hospital General de Agudos “Dr. E. Tornú”, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹Sociedad Argentina de Reumatologia, Cordoba, Argentina, ¹⁰Instituto de Investigaciones, Buenos Aires, Argentina, ¹¹Sociedad Argentina de Reumatologia, La Plata, Argentina, ¹²Sociedad Argentina de Reumatologia, Rosario, Argentina, ¹³Córdoba, Sociedad Argentina de Reumatologia, Córdoba, Argentina, ¹⁴Sociedad Argentina de Reumatologia, Bahia Blanca, Argentina, ¹⁵Sociedad Argentina de Reumatologia, Río Negro, Argentina, ¹⁶Rheumatology, Sociedad Argentina de Reumatologia, Entre Rios, Argentina, ¹⁷Centro de Diagnostico Rossi, Buenos Aires, Argentina, ¹⁸Instituto Reumatológico Strusberg, Córdoba, Argentina, ¹⁹Sociedad Argentina de Reumatologia, Catamarca, Argentina, ²⁰Sociedad Argentina de Reumatologia, Santa Fe, Argentina, ²¹Ramallo 1851, Sociedad Argentina de Reumatologia, CABA, Argentina, ²²Rheumatology Department, Hospital de Rehabilitación Manuel Rocca, Buenos Aires, Argentina, ²³Sociedad Argentina de Reumatologia, Entre Rios, Argentina, ²⁴Rheumatology Department, Hospital Ramos Mejía, Buenos Aires, Argentina, ²⁵Sociedad Argentina de Reumatologia, Mendoza, Argentina, ²⁶Rheumatology Department, Hospital Ricardo Gutierrez, Buenos Aires, Argentina, ²⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²⁸Rheumatology Department, Hospital Rivadavia, Buenos Aires, Argentina, ²⁹Reumatologia, Hospital J M Cullen, Santa Fe, Argentina, ³⁰Rheumatology, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina
Background/Purpose: Biobadasar is a registry that monitors adverse events in patients who use biological treatments in rheumatologic diseases conducted by the Argentine Society of Rheumatology.…
Abstract Number: 280 • 2017 ACR/ARHP Annual Meeting
Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Maria Chiara Ditto¹, Alberto Batticciotto¹, Maria Chiara Gerardi¹, Federica Rigamonti², Rossella Talotta¹ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy
Background/Purpose: immunosuppressive therapies and bDAMRDs expecially, increase the risk of infections. According to the EULAR guidelines, all patients affected by autoimmune/inflammatory diseases should receive vaccinations…
Abstract Number: 1440 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Vaccination Protects from Experimental Arthritis without Affecting Resistance to Mycobacterium Tuberculosis or Listeria Monocytogenes infection
Eric Assier^1,2, Nadia Belmellat^1,2, Luca Semerano^1,2,3, Bernhard Ryffel⁴, Patrice Decker^1,5, Valérie Quesniaux⁴ and Marie-Christophe Boissier^1,5,6, ¹UMR 1125, Inserm, Bobigny, France, ²EA4222, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Service de Rhumatologie, Assistance Publique – Hôpitaux de Paris (AP-HP) Groupe hospitalier Avicenne - Jean Verdier – René Muret, Bobigny, France, ⁴INEM, CNRS UMR7355, Orléans, France, ⁵Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ⁶Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France
Background/Purpose: Anti-TNF-alpha therapy has been a successful treatment strategy for rheumatoid arthritis (RA), but is associated with reduced resistance to infection. In mice, TNF is…
Abstract Number: 272 • 2015 ACR/ARHP Annual Meeting
Are the Autoimmune/Inflammatory Syndrome Induced By Adjuvants (ASIA) and the Undifferentiated Connective Tissue Disease (UCTD) Related to Each Other? a Case-Control Study of Environmental Exposures
Francesco Scanzi¹, Laura Andreoli¹, Maria Martinelli¹, Mara Taraborelli², Ilaria Cavazzana¹, Roberta Ottaviani¹, Nice Carabellese¹, Flavio Allegri¹, Franco Franceschini¹, Nancy Agmon-Levin³, Yehuda Shoenfeld⁴ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Background/Purpose: The Autoimmune/Inflammatory Syndrome induced by adjuvants (ASIA) [1] is an entity that includes different autoimmune conditions observed after exposure to an adjuvant. Patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].